Do analysts rate NEPH or QNRX?

Nephros presently has a consensus target price of $6.00, indicating a potential upside of 64.84%. Given Nephros' stronger consensus rating and higher probable upside, analysts plainly believe Nephros is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor NEPH or QNRX?

In the previous week, Nephros and Nephros both had 2 articles in the media. Nephros' average media sentiment score of 1.33 beat Quoin Pharmaceuticals' score of 0.93 indicating that Nephros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate QNRX or TELA?

TELA Bio has a consensus target price of $2.20, suggesting a potential upside of 155.81%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts clearly believe TELA Bio is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TELA Bio 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts recommend QNRX or NMTC?

NeuroOne Medical Technologies has a consensus target price of $11.67, indicating a potential upside of 236.22%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NeuroOne Medical Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Does the media refer more to QNRX or NMTC?

In the previous week, Quoin Pharmaceuticals and Quoin Pharmaceuticals both had 2 articles in the media. Quoin Pharmaceuticals' average media sentiment score of 0.93 beat NeuroOne Medical Technologies' score of 0.29 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate QNRX or CTSO?

Cytosorbents has a consensus price target of $5.38, indicating a potential upside of 999.18%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts clearly believe Cytosorbents is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer QNRX or CTSO?

In the previous week, Quoin Pharmaceuticals and Quoin Pharmaceuticals both had 2 articles in the media. Quoin Pharmaceuticals' average media sentiment score of 0.93 beat Cytosorbents' score of 0.30 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Quoin Pharmaceuticals (QNRX) Competitors

$4.43 -0.13 (-2.85%)

Closing price 04:00 PM Eastern

Extended Trading

$4.40 -0.03 (-0.68%)

As of 05:01 PM Eastern

Compare

QNRX vs. NEPH, TELA, MLSS, NMTC, and CTSO

Should you buy Quoin Pharmaceuticals stock or one of its competitors? MarketBeat compares Quoin Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quoin Pharmaceuticals include Nephros (NEPH), TELA Bio (TELA), Milestone Scientific (MLSS), NeuroOne Medical Technologies (NMTC), and Cytosorbents (CTSO). These companies are all part of the "medical equipment" industry.

How does Quoin Pharmaceuticals compare to Nephros?

Nephros (NASDAQ:NEPH) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Nephros presently has a consensus target price of $6.00, indicating a potential upside of 64.84%. Given Nephros' stronger consensus rating and higher probable upside, analysts plainly believe Nephros is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nephros has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market.

41.1% of Nephros shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 6.7% of Nephros shares are owned by company insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Nephros and Nephros both had 2 articles in the media. Nephros' average media sentiment score of 1.33 beat Quoin Pharmaceuticals' score of 0.93 indicating that Nephros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nephros	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nephros has a net margin of 4.06% compared to Quoin Pharmaceuticals' net margin of 0.00%. Nephros' return on equity of 7.66% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

Nephros has higher revenue and earnings than Quoin Pharmaceuticals. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	2.10	$1.19M	$0.07	52.00
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

Summary

Nephros beats Quoin Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to TELA Bio?

Quoin Pharmaceuticals (NASDAQ:QNRX) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

In the previous week, Quoin Pharmaceuticals and Quoin Pharmaceuticals both had 2 articles in the media. TELA Bio's average media sentiment score of 0.94 beat Quoin Pharmaceuticals' score of 0.93 indicating that TELA Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Quoin Pharmaceuticals	Positive
TELA Bio	Positive

Quoin Pharmaceuticals has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, TELA Bio has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market.

Quoin Pharmaceuticals has a net margin of 0.00% compared to TELA Bio's net margin of -49.30%. Quoin Pharmaceuticals' return on equity of -489.85% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
TELA Bio	-49.30%	-1,320.81%	-55.83%

TELA Bio has a consensus target price of $2.20, suggesting a potential upside of 155.81%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts clearly believe TELA Bio is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 13.5% of Quoin Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of TELA Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Quoin Pharmaceuticals has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
TELA Bio	$80.28M	0.48	-$38.83M	-$0.79	N/A

Summary

TELA Bio beats Quoin Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Milestone Scientific?

Milestone Scientific (NYSE:MLSS) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Quoin Pharmaceuticals has a net margin of 0.00% compared to Milestone Scientific's net margin of -52.01%. Milestone Scientific's return on equity of -60.26% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Scientific	-52.01%	-60.26%	-40.23%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

Milestone Scientific has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market.

5.8% of Milestone Scientific shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 12.5% of Milestone Scientific shares are held by company insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Milestone Scientific has higher revenue and earnings than Quoin Pharmaceuticals. Milestone Scientific is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Scientific	$8.90M	3.86	-$6.93M	-$0.05	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

Milestone Scientific presently has a consensus target price of $1.00, suggesting a potential upside of 156.41%. Given Milestone Scientific's stronger consensus rating and higher possible upside, equities research analysts clearly believe Milestone Scientific is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Scientific	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than Milestone Scientific. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 1 mentions for Milestone Scientific. Quoin Pharmaceuticals' average media sentiment score of 0.93 beat Milestone Scientific's score of 0.67 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Milestone Scientific	Positive
Quoin Pharmaceuticals	Positive

Summary

Milestone Scientific beats Quoin Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to NeuroOne Medical Technologies?

Quoin Pharmaceuticals (NASDAQ:QNRX) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

NeuroOne Medical Technologies has higher revenue and earnings than Quoin Pharmaceuticals. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
NeuroOne Medical Technologies	$12.10M	2.47	-$3.61M	-$0.85	N/A

Quoin Pharmaceuticals has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -68.35%. NeuroOne Medical Technologies' return on equity of -98.33% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
NeuroOne Medical Technologies	-68.35%	-98.33%	-69.85%

8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 13.5% of Quoin Pharmaceuticals shares are owned by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

NeuroOne Medical Technologies has a consensus target price of $11.67, indicating a potential upside of 236.22%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Quoin Pharmaceuticals and Quoin Pharmaceuticals both had 2 articles in the media. Quoin Pharmaceuticals' average media sentiment score of 0.93 beat NeuroOne Medical Technologies' score of 0.29 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quoin Pharmaceuticals has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Summary

NeuroOne Medical Technologies beats Quoin Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Cytosorbents?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Cytosorbents has higher revenue and earnings than Quoin Pharmaceuticals. Cytosorbents is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
Cytosorbents	$37.06M	0.83	-$8.20M	-$0.19	N/A

Quoin Pharmaceuticals has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Cytosorbents' return on equity of -235.57% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
Cytosorbents	-31.85%	-235.57%	-37.88%

Cytosorbents has a consensus price target of $5.38, indicating a potential upside of 999.18%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts clearly believe Cytosorbents is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 13.5% of Quoin Pharmaceuticals shares are owned by insiders. Comparatively, 7.3% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Quoin Pharmaceuticals and Quoin Pharmaceuticals both had 2 articles in the media. Quoin Pharmaceuticals' average media sentiment score of 0.93 beat Cytosorbents' score of 0.30 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quoin Pharmaceuticals has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

Summary

Cytosorbents beats Quoin Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Quoin Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNRX vs. The Competition

Export

Metric	Quoin Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.16M	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-0.15	17.69	22.39	24.18
Price / Sales	N/A	302.27	520.79	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	0.28	3.85	9.84	6.72
Net Income	-$15.81M	$75.85M	$3.57B	$337.19M
7 Day Performance	-11.40%	-1.67%	-1.16%	0.48%
1 Month Performance	-28.66%	22.18%	3.85%	5.07%
1 Year Performance	-50.28%	21.83%	27.40%	34.25%

Quoin Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNRX Quoin Pharmaceuticals	1.0748 of 5 stars	$4.43 -2.9%	N/A	-47.8%	$9.16M	N/A	N/A	4	News Coverage
NEPH Nephros	2.9787 of 5 stars	$3.57 -0.4%	$6.00 +68.3%	+21.4%	$38.71M	$19.12M	50.94	30
TELA TELA Bio	3.4199 of 5 stars	$0.86 +5.8%	$2.20 +155.5%	-35.9%	$38.54M	$80.81M	N/A	120
MLSS Milestone Scientific	1.5934 of 5 stars	$0.38 +1.9%	$1.00 +163.9%	-58.5%	$33.12M	$8.90M	N/A	30	Gap Down
NMTC NeuroOne Medical Technologies	2.4531 of 5 stars	$3.78 -2.5%	$11.67 +209.1%	+0.1%	$32.54M	$9.72M	N/A	20	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNRX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quoin Pharmaceuticals (QNRX) Competitors

QNRX vs. NEPH, TELA, MLSS, NMTC, and CTSO

How does Quoin Pharmaceuticals compare to Nephros?

Summary

How does Quoin Pharmaceuticals compare to TELA Bio?

Summary

How does Quoin Pharmaceuticals compare to Milestone Scientific?

Summary

How does Quoin Pharmaceuticals compare to NeuroOne Medical Technologies?

Summary

How does Quoin Pharmaceuticals compare to Cytosorbents?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX vs. The Competition

Quoin Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quoin Pharmaceuticals (QNRX) Competitors

QNRX vs. NEPH, TELA, MLSS, NMTC, and CTSO

How does Quoin Pharmaceuticals compare to Nephros?

Do analysts rate NEPH or QNRX?

Which has more volatility & risk, NEPH or QNRX?

Do insiders & institutionals have more ownership in NEPH or QNRX?

Does the media favor NEPH or QNRX?

Is NEPH or QNRX more profitable?

Which has higher earnings and valuation, NEPH or QNRX?

Summary

How does Quoin Pharmaceuticals compare to TELA Bio?

Does the media prefer QNRX or TELA?

Which has more volatility and risk, QNRX or TELA?

Is QNRX or TELA more profitable?

Do analysts rate QNRX or TELA?

Do institutionals & insiders hold more shares of QNRX or TELA?

Which has higher valuation & earnings, QNRX or TELA?

Summary

How does Quoin Pharmaceuticals compare to Milestone Scientific?

Is MLSS or QNRX more profitable?

Which has more risk & volatility, MLSS or QNRX?

Do insiders and institutionals hold more shares of MLSS or QNRX?

Which has better earnings and valuation, MLSS or QNRX?

Do analysts prefer MLSS or QNRX?

Does the media favor MLSS or QNRX?

Summary

How does Quoin Pharmaceuticals compare to NeuroOne Medical Technologies?

Which has stronger earnings and valuation, QNRX or NMTC?

Is QNRX or NMTC more profitable?

Do institutionals and insiders believe in QNRX or NMTC?

Do analysts recommend QNRX or NMTC?

Does the media refer more to QNRX or NMTC?

Which has more risk & volatility, QNRX or NMTC?

Summary

How does Quoin Pharmaceuticals compare to Cytosorbents?

Which has higher earnings and valuation, QNRX or CTSO?

Is QNRX or CTSO more profitable?

Do analysts rate QNRX or CTSO?

Do insiders and institutionals believe in QNRX or CTSO?

Does the media prefer QNRX or CTSO?

Which has more volatility and risk, QNRX or CTSO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX vs. The Competition

Quoin Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools